This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Academic Highlights

Clinical Insights Into Pharmacogenetics and Schizophrenia, Part 2.

John M. Kane, M.D.; Roy H. Perlis, M.D., Ph.D.; and Anil K. Malhotra, M.D.

Published: June 30, 2008

Article Abstract

Click to enlarge page

Dr. Kane: We discussed the clinical relevance that the field of pharmacogenetics has for diagnosing and potentially individualizing treatment for patients with schizophrenia in Part 1 of this ACADEMIC HIGHLIGHTS. In this discussion, we will explore how pharma- cogenetics might help us to identify the relationship between schizophrenia and bipolar disorder as well as manage peripheral problems associated with schizophrenia and bipolar disorder such as cognitive dysfunction and treatment-associated side effects.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 69

Quick Links: